0JDI.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0JDI.L in your mock portfolio yet.
Ionis remains unprofitable, with a negative EPS and a meaningless, highly negative P/E ratio reflecting losses rather than earnings power. While the small per‑share loss (-0.03) suggests losses are not massive on a per‑share basis, the business is still not generating positive net income or sustainable profitability. Overall, current fundamentals lean unfavorably from a pure earnings and valuation standpoint.
The stock trades at $81.75, well above its 200‑day moving average of $44.34, signaling a strong intermediate‑term uptrend. A 2.9% gain over the last month and an RSI of 55.36 indicate positive momentum without signs of extreme overbought conditions. Technically, the setup appears constructive, with price action supporting a bullish bias as long as it remains above key moving averages.
Hiring activity is robust, with 37 open roles and a 54.2% month‑over‑month increase, a strong signal of expansion in R&D, operations, or commercialization. Social media presence, particularly on LinkedIn, is sizable and growing modestly, suggesting a strengthening professional and industry footprint, even as Twitter/X followers are slightly down. Website traffic is very low, but for a B2B, partner‑driven biopharma like Ionis, hiring and professional‑network traction are more meaningful than raw web visits.
Ionis Pharmaceuticals shows strong technical momentum and encouraging alternative data, particularly in hiring and professional‑network presence, which point toward strategic expansion and confidence in its pipeline or future opportunities. However, the company remains unprofitable, and the negative EPS and distorted P/E ratio underscore that the story is still largely speculative and dependent on future clinical and commercial success. Balancing these factors, the overall stance is neutral, with upside potential driven by growth signals but tempered by ongoing fundamental earnings risk.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: